LONDON, UK / ACCESSWIRE / December 18, 2019 / The CMA has published an update in its examination of online platforms and digital advertising, uncovering new detail about how the sector's biggest names operate.

The work is part of the Competition and Markets Authority's (CMA) wider digital strategy, which aims to co-ordinate the authority's approach to tackling the new challenges of the rapidly developing digital economy. The CMA will now consult on the contents of today's update ahead of publishing its final report next year.

In July 2019, the CMA set out to find out more about how major online platforms like Google and Facebook operate. Whilst the services these firms provide appear to be free, consumers pay for them indirectly through providing their attention and personal data, which platforms use to sell digital advertising. In the UK, people spend an average of 3 hours and 15 minutes online each day. More than a third of that time is spent on sites owned by either Google (including YouTube) or Facebook (including Instagram and WhatsApp). As a result, the digital advertising sector has grown massively and is now worth around £13 billion – much larger than any other form of advertising.

The CMA's interim report has found that:

– Last year, Google accounted for more than 90% of all revenues earned from search advertising in the UK, with revenues of around £6 billion
– In the same year, Facebook accounted for almost half of all display advertising revenues in the UK, reaching more than £2 billion

'Big' is not necessarily 'bad' and these platforms have brought very innovative and valuable products and services to the market. But the CMA is concerned that their position may have become entrenched with negative consequences for the people and businesses who use these services every day.

A lack of real competition to Google and Facebook could mean people are already missing out on the next great new idea from a potential rival. It could also be resulting in a lack of proper choice for consumers and higher prices for advertisers that can mean cost rises for goods and services such as flights, electronics and insurance bought online. The market position of Google and Facebook may potentially be undermining the ability of newspapers and other publishers to produce valuable content as their share of revenues is squeezed by large platforms.

Through its market study, the CMA has used its statutory information gathering powers to build a better understanding of this complex market, the drivers behind the positions of Google and Facebook and the competition issues this might present. It has also been able to build a better picture of how these large platforms collect and use personal data to assess whether people have the right amount of control over their own information. All of this will help the CMA identify steps that could open up competition and contribute to the discussion about whether and how best to regulate this sector.

Each year, about 15% of queries on Google have never been searched for before. Other search engines like Bing will not have the same access to these queries, putting Google in a powerful position of being able to better train its algorithms and provide more accurate search results than its rivals.

The CMA has also found that the default settings people are faced with online have a profound effect on choice and the shape of competition. Last year in the UK, Google was willing to pay around £1 billion – 16% of all its search revenues – where it was the default search engine on mobile devices such as Apple phones.

Personal data collection also plays an important role in driving Google and Facebook's powerful market position by allowing them to target their advertisements more effectively than others. Both for privacy and competition reasons, it is essential that people feel in control of their data. At the moment, the CMA is concerned that this is not always the case.

For example, social media platforms such as Facebook do not allow consumers to opt out of personalised advertising: rather, people are presented with a take-it-or-leave it offer, forcing them to share considerable amounts of personal data as a condition for using the service. And it is difficult to access privacy settings on these platforms, which are often only visible after navigating through multiple menus.

While there are examples of better practice, with search engines such as Google giving consumers better control, overall, we have found that consumer engagement with privacy settings and controls is low and, that, as a result, most consumers follow the default settings set by platforms – which may result in them giving up more data than they would like.

The CMA is also concerned about a lack of transparency in the way that business on these platforms works. Publishers, such as newspapers, who rely on Google and Facebook for about 40% of their traffic, have expressed concerns about unexplained dramatic changes in the number people visiting their websites due to changes in Google's search and Facebook's news algorithms. Different sorts of transparency concerns are particularly acute in the market for display adverts, where advertisers and publishers participate in a 'black box' process of real-time bidding but have limited ability to verify the effectiveness of their adverts.

CMA Chief Executive Andrea Coscelli said: "Most of us visit social media sites and search on the internet every day, but how these firms work can be a mystery.

"So far in this study, we have used our legal powers to discover how major online platforms operate. Digital advertising fuels big businesses like Google and Facebook and we have been building a picture of how this complex new market works. We've looked especially at how these firms collect and use people's data, how they monetise it and what this means for rival companies who want to compete, as well as the people and businesses using these services every day.

"We're now inviting comments on what we have found. At the end of the study, we'll present our findings to the new Government as they decide whether and how to regulate what is an increasingly central sector in all our lives."

At this stage, the CMA agrees with Professor Furman and his colleagues who carried out a wide-ranging review of digital markets earlier this year, that there is a strong argument for the development of a new regulatory regime. This could include rules governing the behaviour of online platforms and giving people greater control over their own data. The most likely outcome at the end of this study will be recommendations to the new Government as it decides whether and how to regulate the digital sector. On the other hand, the CMA stands ready to act directly through any or all of its own powers if, ultimately, these issues are not addressed in other ways, whether domestically or internationally.

Many of the problems that the CMA has currently identified are international in nature. The Australian Government's recent decision to create a digital markets unit and the new draft legislation in Germany on competition and digital markets demonstrates the international will to address what are shared challenges with new solutions. The CMA has taken a leading role in these global discussions for some time now and will continue to further the debate as part of its digital strategy.

While still early in its work, the CMA is also setting out proposals that it thinks are worth considering in order to address the issues it has identified. These reflect the ideas market participants have put to us and include: potential measures to open up the search market, such as access to click and query data and limiting Google's ability to be the default search engine on devices and browsers; requiring Facebook to connect more seamlessly with rival social networking sites; measures to address the conflicts of interests and lack of transparency in digital advertising and requiring platforms to allow people to turn off personalised advertising.

The CMA is now consulting on its interim report and welcomes views by 12 February 2020. Find out more on the online platforms and digital advertising market study web page.

Notes to editors

1. The CMA is the UK's primary competition and consumer authority. It is an independent non-ministerial government department with responsibility for carrying out investigations into mergers, markets and the regulated industries and enforcing competition and consumer law. For CMA updates, follow us on Twitter, LinkedIn and Facebook.

2. Media queries should be directed to: press@cma.gov.uk or 020 3738 6460.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Competition and Markets Authority

ReleaseID: 570644

First program from the Topas platform to enter clinical testing
TPM203 is one of several proprietary programs being developed by Topas
Pemphigus vulgaris is an orphan indication that currently has no cure

HAMBURG, GERMANY / ACCESSWIRE / December 18, 2019 / Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris (PV), an orphan autoimmune disease. TPM203 is Topas' most advanced program and the first one from the Company's proprietary Topas Particle Conjugates (TPC) platform technology to enter the clinic.

"The initiation of the first clinical study with our lead product candidate is an exciting and at the same time value-generating step forward for Topas," said Timm Jessen, PhD, Chief Executive Officer. "Pemphigus vulgaris is a well characterized disease with extensive knowledge on the most related autoimmune antigen and biomarkers available. It provides a very good setting to demonstrate the successful translation of our Topas Particle Conjugates platform into the clinic. While treatments do exist for this painful condition, there currently is no cure, and we look forward to advancing TPM203 with the goal of helping patients with this debilitating disease."

The Phase 1 trial is an open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of TPM203, as well as to explore early signs of effectiveness for TPM203 to induce antigen-specific immune tolerance in this patient population. The study has a single-ascending dose phase, followed by a multiple dose phase. The trial is planned to treat 24 patients and will be conducted at approximately seven sites in Germany; the coordinating investigator is Prof. Michael Hertl from the Dept. of Dermatology and Allergology at University Medical Center Marburg.

Topas Particle Conjugates technology platform harnesses the liver's natural immunology capabilities

Topas' technology platform harnesses the natural mechanisms of the liver to promote immune tolerance to blood borne antigens. Small peptide-loaded nanoparticles, Topas Particle Conjugates (TPCs), mimic such blood borne antigens and are taken up by liver sinusoidal endothelial cells (LSECs). LSECs present these antigens to T cells under anti-inflammatory conditions conducive to the induction of tolerogenic regulatory T cells (Tregs) and/or by other mechanisms. Tregs are pivotal for immune tolerance, and their in vivo generation serves to re-instate healthy immune balance (homeostasis) and provide a cure for diseases characterized by undesirable or dysregulated inflammatory immune reactions. The fast and active uptake of circulating TPCs by LSECs leads to rapid clearance of the particles from the bloodstream, allows an exact dosing of the antigen residing in the liver and avoids undesired immune reactions. TPCs provide major competitive advantages, including in vivo traceability, dose-ability, biodegradability and scalability along GMP requirements.

About Pemphigus Vulgaris

PV, an orphan disease, is an autoimmune condition involving a painful blistering on the skin and mucous membranes. If extensive, blistering can lead to life-threatening fluid loss, infection, and disfigurement. In this disease, patients have autoantibodies against desmogleins (proteins that play a role in connecting cells), which disrupt the connections between the squamous cells of the epidermis and cause blisters that can easily burst. Treatment consists of immunosuppressive agents; prognosis is variable, but many patients have a higher than normal mortality rate, and there is no cure.

About Topas Therapeutics

Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver's natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas' investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. For additional information, please visit: www.topas-therapeutics.com.

Contacts:

Media Relations Europe
Topas Therapeutics GmbH
MC Services AG
Dr. Timm-H.
Jessen Anne Hennecke
CEO / Managing Director Phone
+49 211 529 252 22
Falkenried 88
Email anne.hennecke@mc-services.eu     

Media Relations U.S.  
Laurie Doyle  
Phone +1 339 832 0752
Email jessen@topas-therapeutics.com
Email laurie.doyle@mc-services.eu
Web www.topas-therapeutics.com
Web www.mc-services.eu

SOURCE: Topas Therapeutics GmbH

ReleaseID: 570643

Recent graduate of the Berkeley SkyDeck accelerator, Humm is working with leading neuroscientists to bring its first patch to market; making neurostimulation technology 100-times cheaper and allowing users to experience the benefits in three minutes

SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2019 / Humm, a neuroscience company focused on helping people continue to learn and grow throughout their lives, today announces it has raised an additional $2.6 million seed round, bringing its total disclosed funding to $3.1 million. The funding round was led by Blueyard Capital with additional funding from CRCM Venture Capital and follow-on funding from the Berkeley SkyDeck Fund. Joining the company's board are Jason Whitmire, General Partner of Blueyard and Ariel Poler. Poler is a prominent Silicon Valley entrepreneur, investor and long-standing executive of the successful consumer health company Strava and UCSF's Health Hub.

Funds will be used to launch Humm's first product, a wearable patch and software app that makes learning faster and easier by strengthening the neural circuits which regulate memory in the brain. The Humm patch is the first technology that has been shown to measurably improve working memory within just minutes of use, and for hours after. A person's working memory determines how many numbers, names and other facts they can hold in mind at any time, and improving it allows a user to do things like learn skills and information faster, focus better and multitask more effectively.

Ciarán O'Leary, General Partner at Blueyard Capital stated, "As software and biology continue to be on a collision course, new technology paradigms will emerge that will unleash creativity and empower scientists, clinicians and engineers to read, edit and write biology – including key human functions. Humm's technology improves the performance of the human mind and has the potential to expand healthspan for millions of people. So we are excited to be working with a team that is reinventing the form factor and experience of brain stimulation."

"This is a very important time for Humm," said Iain McIntyre, Humm CEO and Co-founder. "Using the patch is as easy as sticking on a BAND-AID®–nothing bulky or awkward. In a 15-minute session, our clinical trial shows a 20 percent improvement in working memory capacity [against placebo] within the first three minutes of wearing a patch, that then lasts for more than an hour afterwards. In our testing with hundreds of early access users this year we've seen people doing exciting things with that boost, like accelerating the speed they can learn a language or remembering more of what they read."

Working with top neuroscientists in the field of neurostimulation at UC Berkeley and UCSF, Humm is continuing to refine the easy-to-use and inexpensive (less than $10) patch. The product is worn on the forehead, just above the prefrontal cortex–a critical area of the brain for decision making and learning. It uses non-invasive electrical stimulation, which has been studied for the past 30 years and Humm's particular method of choice, known as tACS, takes advantage of some of the latest exciting research in the area.

The company's early access store is now closed after receiving thousands of pre-orders from customers and a substantial order from the U.S. Airforce, but those wanting to be among the first to try may join a waitlist at www.thinkhumm.com. Humm plans to make the patch available to consumers in Q3 2020. The product will be demonstrated at the upcoming CES conference in Las Vegas January 2020. (Demo at the SkyDeck exhibit at the RAVV booth in Eureka Park– #51263).

Added Mcintyre "Our vision is to use this novel technology to replace medication and supplementation for the brain with a healthier, better alternative that nurtures and improves our mental capabilities." Humm is now hiring engineers (hardware and software) and other positions – seeking people who are excited to help realize this vision – see thinkhumm.com/jobs.

About the Venture Capital Firms

BlueYard Capital is a venture investment firm based in Berlin that backs founders with transformative ideas that empower humanity. The firm invests in early stage companies creating novel technologies that have the potential to solve the planet's biggest problems and transform society for the better, including quantum computing, nuclear fusion reactors, lab-grown meat and blockchain systems.

CRCM Ventures, based in San Francisco, is an early investor in several prominent consumer tech companies such as Musical.ly (Tiktok) and Youku (the Youtube of China).

These new investors join previous investors, Berkeley SkyDeck, one of the world's top university accelerators, Kai Huang, creator of the hit game Guitar Hero, and the company's original Australian backers Larsen Ventures and Spacecubed.

For more information about the company, or to download their white paper visit www.thinkhumm.com.

Images:https://drive.google.com/drive/folders/1_GfUp0RyuzzBgzXi-5ziwe4ivXDX-pOm
Clinical Study:Humm White Paper

Media Contact:

Erica Zeidenberg
erica@hottomato.net
925-518-8159 mobile
925-631-0553 office

SOURCE: HUMM

ReleaseID: 570633

ORLANDO, FL / ACCESSWIRE / December 18, 2019 / Cyclo Therapeutics, Inc. (OTCQB:CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, received a buy recommendation and $1.25 price target from ThinkEquity, a division of Fordham Financial Management.

ThinkEquity's research report on Cyclo Therapeutics focused primarily on the company's development of a treatment for Niemann-Pick Disease Type C (NPC), a rare and fatal genetic disease.

Assuming continued positive results from clinical trials underway, the report forecasts Cyclo Therapeutics will receive FDA approval and begin generating revenue from its NPC treatment in 2022, with estimates of a potential $75 million in annual sales in the US.

While the ThinkEquity analyst notes the company's recently announced development program for Alzheimer's Disease (AD), it stops short of including any potential upside from the program in its current price target forecast.

As additional milestones are achieved in the AD program, the price target could be revised significantly higher.

Positive Results in NPC and AD Development Programs

Cyclo Therapeutics recently published the most extensive set of case studies to-date on expanded access use (or "compassionate use") of hydroxypropyl beta cyclodextrin to treat patients with NPC.

The manuscript was published on October 21, 2019 in the Orphanet Journal of Rare Diseases, a scientific, peer-reviewed publication (see https://www.ncbi.nlm.nih.gov/pubmed/31639011).

Eighty percent of the patient use data presented in the manuscript derives from Cyclo Therapeutics' Trappsol® Cyclo™ product, the company's proprietary formulation of hydroxypropyl beta cyclodextrin.

In an extensive review of the data, hydroxypropyl beta cyclodextrin was found to be safe when administered intravenously, and individual patients showed improvements in disease symptoms.

Other highlights of the manuscript are that physicians noted that their patients receiving intravenous cyclodextrin showed improvements in ability to walk and to write, increased alertness, improved ability to communicate, and enhanced overall well-being.

As well, individual treated patients exhibited reduction in hepatic volume and improvement in liver transaminases, restoration of language skills, and resolution of interstitial lung disease.

Similar positive early findings have been reported by Cyclo Therapeutics in its work in AD.

Cyclo Therapeutics has been intravenously administering its proprietary Trappsol® Cyclo™ product to a late-onset Alzheimer's patient for more than a year under an FDA compassionate use program.

In a required annual report to the FDA filed in May 2019, the company reported data that suggest a positive safety profile for the drug in the Alzheimer's patient, overall stabilization of disease, and improvement in certain behavioral aspects of the disease. Given that persons with late-onset AD dementia are generally expected to decline during a one-year timeframe, the results with this patient are extremely promising.

"The report suggests cognitive and neurologic stability, indicating possible benefit," said Dr. Sharon Hrynkow, Cyclo Therapeutics' Chief Scientific Officer.

The expanded access program has been funded externally, with Cyclo Therapeutics providing key materials, expertise, and support, in addition to the drug itself.

Phase I/II Trials Underway in NPC

NPC is a rare and fatal genetic disease affecting 1 in 100,000 live births globally.

NPC affects every cell in the body due to the defect in the NPC protein which is responsible for cholesterol processing in the cell. Because of the NPC protein defect, cholesterol accumulates abnormally in every cell in the body, causing symptoms in the brain, liver, spleen, lungs, and other organs. There are no approved drug therapies for NPC in the United States, and only one, Miglustat/Zavesca, in Europe.

Trappsol® Cyclo™, the same drug used in Cyclo Therapeutics' Alzheimer's patient compassionate use program, is already in Phase I/II trials for NPC. A Phase I trial in the US has completed enrollment, with top-line results expected in early 2020.

In 2019, Cyclo Therapeutics presented initial findings from the Phase I and Phase I/II trials at multiple medical conferences, showing promising results for drug safety and efficacy in NPC. Specifically, Trappsol® Cyclo™ clears cholesterol from cells as shown by blood biomarkers of cholesterol synthesis and metabolism and by liver histology. Initial results from the Phase I/II trial show benefit of the drug on neurologic features of the disease, consistent with earlier findings from compassionate use programs.

Trappsol® Cyclo™ has been granted Orphan Drug Designation (ODD) by the FDA and European Medicines Agency, as well as both Rare Pediatric Disease and Fast Track designations in the US. ODD gives Cyclo Therapeutics market exclusivity for 7 and 12 years in the US and EU, respectively.

Alzheimer's Is Currently the Most Common Form of Dementia

According to the Alzheimer's Association, 5.8 million Americans are living with Alzheimer's Disease. By 2050, this number is projected to rise to nearly 14 million.

It's estimated that Alzheimer's and other dementias cost the US $290 billion annually. These costs could rise as high as $1.1 trillion by 2050.

Despite its prevalence, after more than 30 years of research, there is still no cure for Alzheimer's, and only a handful of medications have reached the market.

Leading CRO to Conduct Alzheimer's Clinical Trial

In November, Cyclo Therapeutics signed an agreement with Worldwide Clinical Trials, a leading Contract Research Organization (CRO), to conduct a clinical trial to evaluate the safety and efficacy of the company's Trappsol® Cyclo™ in AD.

Worldwide is an award-winning company that has been recognized by organizations from around the world for its outstanding services and expertise, receiving numerous awards and rankings by respected industry associations and awards programs, including Informa's Scrip Awards, Life Science Leader's CRO Leadership Awards, and Nice Insight, the research division of That's Nice, A Science Agency.

Founded by physicians and scientists dedicated to advancing medical science and build on an unwavering commitment to operational excellence, Worldwide is able to strategically balance science, medicine, operations, and commercial intelligence to achieve successful drug development.

Worldwide employs more than 1,700 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia.

From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, Worldwide provides world-class, full-service drug development services.

"The scientific, medical and operational experts at Worldwide offer nearly 40 years of hard-won insight gleaned from our experience on the front lines of Alzheimer's Disease research. The journey toward halting progression of this devastating neurodegenerative disorder takes tenacity, and we're not about to give up now," said Henry Riordan, PhD, executive vice president, Scientific Solutions, and Co-Founder of Worldwide. "We are thrilled to be selected by the innovators at Cyclo Therapeutics as their partner in the development of this exciting new treatment approach."

Cyclo Therapeutics and Worldwide are designing the trial protocol and expect to schedule a scientific advice meeting with the U.S. FDA in early 2020. Patient enrollment is expected to begin shortly thereafter.

Board Members Invest $10M+ into Cyclo Therapeutics

Board members at Cyclo Therapeutics, including multiple outside directors, have invested more than $10 million into the company in recent years, including more than half a million shares purchased since May of this year alone.

Board member Markus Sieger, President and CEO of Polpharma Group, purchased 100,000 shares in August, increasing his total position to more than 4.5 million shares. Polpharma is among the top 20 generic drug manufacturers in the world. Its portfolio includes about 600 products and another 200 in development.

Patrick Ostronic, an officer of US Pharmacia International and CFO of its parent company, The USP Group, personally purchased 350,000 shares of Cyclo Therapeutics in the weeks following the company announcing its plans to launch an Alzheimer's trial. As of the latest filing, Ostronic himself owned more than 1.3 million shares of Cyclo Therapeutics. USP has been a trend setter in the OTC medicine market for over 20 years and is currently the leading company in the OTC sector of the Polish pharmaceutical market, employing around 700 people across Eastern Europe and the United States with a portfolio of more than 100 products.

Former President & COO of Colgate-Palmolive Owns 2.5M+ Shares

Also serving on Cyclo Therapeutics' board is William Shanahan, the retired President and COO of Colgate-Palmolive. Shanahan joined Cyclo Therapeutics' board in 2016 and now owns more than 2.6 million shares of Cyclo Therapeutics as of the latest filings, which include his 800,000-share purchase in May 2019 and his purchase of 415,000 shares in August and September 2019.

Low Valuation Relative to Potential Upside

With a $500M+ annual addressable market in NPC and a $1B+ annual addressable market in AD, Cyclo Therapeutics offers a compelling opportunity for potential upside from its current valuation, and with an institutional round of $7.4 million in equity financing closed in 2019, Cyclo Therapeutics has a strong balance sheet to move its programs forward.

Despite these and many other strengths, the company's stock trades for a market cap of less than $30 million. As the company continues to achieve major milestones and more investors learn of the opportunity, shares could begin moving toward a more realistic and higher valuation.

Learn more about Cyclo Therapeutics, its work in Alzheimer's, and its clinical trials for NPC, by visiting CTDHinfo.com, where you can sign up for free news alerts to stay abreast of the latest developments of this exciting opportunity.

Additional information is available at the company's website and in their latest investor presentation.

About RedChip Companies, Inc.

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 27 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered on-line weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; investor webinars and group calls; a globally-televised show, "The RedChip Money Report," which airs in 149 million homes globally on Bloomberg International; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Disclaimer: RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).

Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.

Cyclo Therapeutics (OTCQB: CTDH) is a client of RedChip Companies, Inc. CTDH paid RedChip Companies, Inc. a fee of $30,000 per month for four months, beginning in August 2019, and a monthly fee of $7,500, beginning December 2019, for RedChip investor awareness services and consulting services. RedChip's CEO owns 146,128 shares of CTDH stock. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.

Contact:
Dave Gentry, CEO
RedChip Companies
407-644-4256
dave@redchip.com

SOURCE: Cyclo Therapeutics

ReleaseID: 570640

BALA CYNWYD, PA / ACCESSWIRE / December 18, 2019 / Brodsky & Smith, LLC reminds investors of important approaching deadlines regarding class action lawsuits against the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.

SEALED AIR CORPORATION (NYSE:SEE)

Shares purchased between November 5, 2014 and August 6, 2018

Deadline: December 31, 2019

According to the complaint, throughout the Class Period, the defendants failed to disclose the following adverse facts pertaining to Sealed Air's business, operations and financial condition, which were known to or recklessly disregarded by the defendants: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate the defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating Sealed Air's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Additional information can be found at http://www.brodskysmith.com/cases/sealed-air-corporation-nyse-see/, or call 877-534-2590. No cost or obligation to you.

UNDER ARMOUR, INC. (NYSE:UA and UAA)

Shares purchased between August 3, 2016 and November 1, 2019

Deadline: January 6, 2020

According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) Under Armour had been under investigation by and cooperating with the DOJ and SEC since at least July 2017; and (3) as a result, the defendants' statements about Under Armour's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Additional information can be found at http://www.brodskysmith.com/cases/armour-inc-nyse-ua-uaa/, or call 877-534-2590. No cost or obligation to you.

BAXTER INTERNATIONAL (NYSE:BAX)

Shares purchased between February 21, 2019 and October 23, 2019

Deadline: January 24, 2020

According to the complaint, throughout the Class Period, defendants misrepresented and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) Baxter lacked effective internal control over financial reporting; (3) as a result, Baxter's financial statements were misstated and would likely require correction or amendment; (4) due to Baxter's internal investigation, it would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on a Form 10-Q in a timely manner; and (5) as a result of the foregoing, defendants' statements about Baxter's business and operations lacked a reasonable basis.

Additional information can be found at http://www.brodskysmith.com/cases/baxter-international-nyse-bax/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 570422